Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
about
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.The molecular pathogenesis and management of bronchial carcinoids.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Yttrium-labelled peptides for therapy of NET.Lutetium-labelled peptides for therapy of neuroendocrine tumours.Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.Therapeutic strategies for neuroendocrine liver metastases.Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of lifePeptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.Radionuclide Therapy for Neuroendocrine Tumors.68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.Challenging Management of Neuroendocrine Tumor With Hepatic Metastasis and Carcinoid Heart Disease in a Child.How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective.
P2860
Q34157391-2ABFD958-954D-4722-A503-4E95D627DF2CQ35371197-435289B1-3AB9-4FEE-B0D5-8CDF1D514A5AQ35724907-98560705-A6D1-43B8-BFE9-453C97245941Q36516035-047564D5-5B58-4ED6-8D38-85FDC51BD398Q37833109-EEB7ACB2-FF87-4381-BE1E-F2B357AA299BQ37975101-4AFF0ED3-AF48-43BE-B816-2D8E8D9289C8Q37990401-D27D724A-DAE7-4141-8486-69038A0DFDD6Q37990411-E0385A49-CA90-4D2C-B519-18EA8BE9BCD0Q38241601-5072B25A-1C1E-439A-93C8-D740FBABC9B2Q38255979-7BB1228D-9BD0-4C2E-ADC0-BD256EDE1E69Q38557054-5F404CA7-E1A1-41FD-8874-32031CA0259AQ38756968-321C2650-653C-4522-9AD1-2E18DDFA0594Q38909078-EDB2B250-A139-461F-BF82-81F414EA0A37Q38936576-5C2B5B4B-4D1E-47D5-B055-5023ECAF5827Q39144880-4F4069E2-7DB8-4797-BF7C-FE6AB1B1C912Q39689821-84B37ADB-5D6C-4406-B21B-6C8409627F41Q40043517-9832B233-B818-4B3E-BC37-D267B4A338FDQ42345704-CBF83F6A-85DF-4B98-BAFC-8FAB9E3B691FQ46111876-B9E97AD9-E2B7-4B46-9A96-FAD7192CC75BQ47589004-CE72A821-3042-43F4-B431-7ABFDC579445Q51366001-EB83724A-C653-44CF-9288-6923BAC3948CQ52881909-F254960E-EEA9-4A72-BE25-981B0BC48DE6
P2860
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@ast
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@en
type
label
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@ast
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@en
prefLabel
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@ast
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@en
P2093
P1476
Salvage therapy with (177)Lu-o ...... creatic neuroendocrine tumors.
@en
P2093
Boen L R Kam
Dik J Kwekkeboom
Eric P Krenning
Martijn van Essen
Richard A Feelders
P304
P356
10.2967/JNUMED.109.068957
P407
P577
2010-02-11T00:00:00Z